Table 3 Comparison of miR-1260a, and miR-1260b expression levels, and the clinical features of patients
From: High expression level of miR-1260 family in the peripheral blood of patients with ovarian carcinoma
Features | miR-1260a | Expression | miR-1260b | Expression | |
|---|---|---|---|---|---|
Expression Level | Increased | Decreased | Increased | Decreased | Total |
n (%) | n (%) | n (%) | n (%) | n(%) | |
Mean age 50 ± 10 y(25-84y) | |||||
40 y> | 11 (8.7%) | 5 (3.9%) | 13 (10.2%) | 3 (2.4%) | 16 (12.5%) |
40 y≤ | 72 (56.7%) | 39 (30.7%) | 31 (24.4%) | 80 (63%) | 111 (87.5%) |
Total n (%) | 83 (65.3%) | 44 (34.7%) | 44 (34.7%) | 83 (65.3%) | 127 |
Clinical Stage | |||||
Stage 1 | 12 (9.4%) | 10 (7.9%) | 14 (11.0%) | 8 (9.3%) | 22 (17.3%) |
Stage 2 | 13 (10.2%) | 1 (0.8%) | 13 (10.2%) | 1 (0.8%) | 14 (11%) |
Stage 3 | 49 (38.6%) | 27 (21.3%) | 56 (44.1%) | 20 (15.7%) | 76 (59.9%) |
Stage 4 | 9 (7.1%) | 6 (4.7%) | 10 (7.9%) | 5 (%3.9) | 15 (11.8%) |
Total n(%) | 83 (65.3%) | 44 (34.7%) | 93 (73.2%) | 34(26.8%) | 127 |
Pathological Grade | |||||
Grade 1 | 11 (8.7%) | 11 (8.7%) | 16 (12.6%) | 6 (%4.7) | 22 (17.3%) |
Grade 2 | 14 (11.0%) | 5 (3.9%) | 14 (11.0%) | 5 (3.9%) | 19 (15%) |
Grade 3 | 58 (45.7%) | 28 (22.0%) | 63 (49.6%) | 23 (18.1%) | 86 (67.7%) |
Total n(%) | 83 (65.3%) | 44 (34.6%) | 93 (73.2%) | 34 (26.8%) | 127 |
Histological Grade | |||||
Grade 1 | 12 (9.4%) | 13 (10.2%) | 16 (12.6%) | 9 (7.1%) | 25 (19.6%) |
Grade 2 | 13 (10.2%) | 11 (8.7%) | 17 (13.4%) | 7 (%5.5) | 24 (18.9%) |
Grade 3 | 58 (45.7%) | 20 (15.7%) | 60 (47.2%) | 18 (14.2%) | 78 (61.5%) |
Total n(%) | 83 (65.3%) | 44 (34.6%) | 93 (73.2%) | 34 (26.8%) | 127 |
Tumor Size | |||||
<2cm | 18 (14.2%) | 10 (7.9%) | 20 (15.7%) | 8 (6.3%) | 28 (22%) |
≥2cm | 65 (51.2%) | 34 (26.8%) | 73 (57.5%) | 26 (20.5%) | 99 (78%) |
Total n(%) | 83 (65.3%) | 44 (34.6%) | 93 (73.2%) | 34 (26.8%) | 127 |
Treatment | |||||
Surgery | |||||
Yes | 78 (63.9%) | 44 (32.1%) | 87 (69.0%) | 34 (27.0%) | 122 (96%) |
No | 5 (4.0%) | 0 (0.0%) | 5 (4.0%) | 0 (0.0%) | 5 (4%) |
Total n(%) | 83 (65.3%) | 44 (34.6%) | 93 (73.2%) | 34 (26.8%) | 127 |
Chemotherapy | |||||
Yes | 78 (66.1%) | 40 (25.9%) | 86 (68.3%) | 30 (23.8%) | 118 (92.9%) |
No | 5 (4.0%) | 5 (4.0%) | 6 (4.8%) | 4 (3.2%) | 10 (7.1%) |
Total n(%) | 83 (65.3%) | 44 (34.6%) | 93 (73.2%) | 34 (26.8%) | 127 |
Radiotherapy | |||||
Yes | 10 (7.9%) | 5 (4.0%) | 10 (7.9%) | 5 (%4.0%) | 15 (11.8%) |
No | 73 (57.4%) | 39 (30.7%) | 82 (65.1%) | 29 (23.0%) | 112 (88.2%) |
Total n(%) | 83 (65.3%) | 44 (34.6%) | 93 (73.2%) | 34 (26.8%) | 127 |
Ovarian & Breast cancer histories in the family | |||||
<2 persons | 52 (40.9%) | 31 (24.4%) | 59 (46.5%) | 24 (%18.8%) | 83 (65.3%) |
≥2 persons | 31 (24.4%) | 13 (10.3%) | 34 (26.8%) | 10 (7.9%) | 44 (34.7%) |
Total n(%) | 83 (65.3%) | 44 (34.7%) | 93 (73.2%) | 34 (26.8%) | 127 |